Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etanercept. Immunex.

M K Pugsley1

  • 1Department of Pharmacology, Xoma (US) LLC, Berkeley, CA 94710, USA. PUGSLEY@xoma.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Etanercept, a soluble TNF receptor fusion protein, is approved for rheumatoid arthritis and investigated for other conditions. Development for congestive heart failure was halted due to efficacy concerns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation.

Regulatory toxicology and pharmacology : RTP·2024
Same author

The antiarrhythmic actions of bisaramil and penticainide result from mixed cardiac ion channel blockade.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2018
Same author

Corrigendum to An overview of the safety pharmacology society strategic plan [Journal of Pharmacological and Toxicological Methods 93 (2018) 35-45].

Journal of pharmacological and toxicological methods·2018
Same author

Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2018
Same author

An overview of the safety pharmacology society strategic plan.

Journal of pharmacological and toxicological methods·2018
Same author

An overview of the safety pharmacology career of Dr. C.R. Hassler.

Journal of pharmacological and toxicological methods·2017
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Biopharmaceuticals
  • Rheumatology
  • Immunology

Background:

  • Etanercept is a soluble tumor necrosis factor receptor (TNFR) fusion protein developed by Immunex.
  • It is indicated for rheumatoid arthritis (RA) and investigated for other TNF-mediated conditions.

Purpose of the Study:

  • To evaluate the efficacy and market potential of etanercept for various indications.
  • To track the drug's development progress, regulatory status, and sales performance.

Main Methods:

  • Review of clinical trial phases (Phase III) and regulatory filings (NDA, sBLA).
  • Analysis of sales data and market projections from financial institutions (Merrill Lynch, Morgan Stanley).

Main Results:

  • Etanercept launched for moderate-to-severe RA in the US and EU; Priority Review granted for psoriatic arthritis.

Related Experiment Videos

  • Development for congestive heart failure (CHF) halted due to lack of statistical significance in efficacy endpoints.
  • Significant sales achieved, with projections exceeding $2 billion annually by 2004 and potential for over $5 billion in the US.

    • Conclusions:

    • Etanercept demonstrates strong market performance and revenue generation for RA.
    • Development challenges were encountered for CHF, highlighting the importance of efficacy endpoints.
    • The drug's commercial success underscores its significance in treating RA and potential in other inflammatory conditions.